Indigo HALO continuous multi-metabolite monitor
Indigo Diabetes NV
A technically distinct route to continuous context — still an early implant programme, not a CGM you can buy or trust for dosing.
What it is
An investigational implantable spectrometer intended to monitor glucose, ketones and lactate continuously for about a year. A seven-person predecessor study showed proof of concept, a six-month feasibility study is only company-reported, and the new 12-person HALO BRIGHT study has not started. It is neither FDA-cleared nor CE-marked.
Editorial review: .
Most recent recorded citation date: 2026-08-04. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Accuracy: The YANG predecessor reported 7.1% overall glucose MARD in only four T1D participants under induced challenges, using within-study spectral-model cross-validation. That is proof of concept, not market-grade validation.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- The manufacturer explicitly states that the product is not FDA-cleared, not CE-marked and not for sale.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 45 × 20 + 30 × 15 + 5 × 15 + 55 × 10 + 35 × 10 + 20 × 10 + 55 × 10 + 80 × 5 + 0 × 5 = 3475; divide by total weight 100. Unrounded weighted result: 34.75.
The YANG predecessor reported 7.1% overall glucose MARD in only four T1D participants under induced challenges, using within-study spectral-model cross-validation. That is proof of concept, not market-grade validation.[1]
The published prototype was powered only during supervised measurement visits; continuous ambulatory lag and rapid-change performance are not established.[1]
No pump or AID integration exists. The planned phone connection and data sharing remain development features.[2]
A one-year replacement interval is the development target, but published peer-reviewed data cover 28 days; the company reports six-month spectral monitoring without publishing full performance results.[3]
The enzyme-free spectrometer is intended not to require calibration, but that claim has not been demonstrated in a pivotal or market-use study.[2]
Real-time phone trends and warnings are planned, not validated in an approved product.[2]
Invisible once implanted and potentially worn for a year, but insertion and removal are procedures; the predecessor required a 35 mm incision by a surgeon.[1]
Simultaneous ketone and lactate sensing is the platform's defining value; it was demonstrated in a tiny predecessor study and remains to be validated continuously in HALO.[1]
Editor’s take
HALO belongs on the horizon because it combines the signals a future AID system actually needs, not because a seven-person prototype has solved CGM. The decisive evidence will be stable, continuously powered performance across months — especially in hypoglycemia and ketosis — followed by a system that can safely drive decisions outside a supervised lab.
The full picture
Most continuous glucose monitors are disposable enzyme sensors that measure one thing for one or two weeks. Indigo HALO takes a different route: a tiny near-infrared spectrometer implanted under the skin, designed to read the light absorption pattern of several metabolites at once — initially glucose, ketones and lactate — and send them to a phone.2 Indigo's target is roughly annual replacement, potentially longer later.2
That could matter. Ketones can warn that insulin delivery has failed before
full diabetic ketoacidosis develops; lactate may add exercise and metabolic
stress context. A loop that sees only glucose is trying to steer while blind to
both. HALO's new multi-metabolite tag marks that distinction: this is not just
another glucose sensor in a smaller shell.
What has actually been shown
The published human evidence is still the YANG predecessor, not a finished HALO product. In GLOW, seven people — only four with T1D — carried the implant for 28 days and attended supervised metabolic-challenge visits. Six sensors remained operational; the paper reported no infection or wound-healing complications. In the four T1D participants, exploratory glucose modelling reported 7.1% overall MARD, while the sensor also tracked induced ketone, lactate and ethanol changes.1
Those numbers are intriguing and very easy to overread. The device was powered during study visits, the sample was tiny, the spectral model was cross-validated inside the same experiment, the study was company-funded, and Indigo employees were authors.1 It was proof that the spectroscopy signal could work — not proof of a year-long dosing-grade CGM.
Indigo says its later SHINE study collected spectral data for six months with no device-related serious adverse events and positive usability, but it has not published participant-level accuracy or a full results paper on the page making those claims.3 We therefore treat SHINE as a company-reported feasibility update, not a validated accuracy result.
The August 2026 change
On 4 August, the first registry record naming HALO appeared. BRIGHT plans to implant 12 adults with T1D diagnosed for at least 12 months who use CSII for three months. Its primary performance endpoints compare HALO's glucose, ketone and lactate values with venous reference measurements and test whether that accuracy stays stable over the implant period; it also measures procedure and device safety.4 It is not yet recruiting, has no posted locations and is expected to run from December 2026 to June 2027.
HALO remains investigational. Indigo's own product page explicitly states: not FDA-cleared, not CE-marked and not for sale.2 A path to a discreet, multi-signal implant now exists; the evidence needed to trust it for everyday decisions does not yet.
Coming soon
ETA · BRIGHT 12-person implant study expected to run December 2026-June 2027; no regulatory submission or launch date announced
- →BRIGHT study of HALO glucose, ketone and lactate accuracy and stability versus venous reference measurements, plus implantation safety · estimated December 2026-June 2027
Sources
- [1]Early feasibility study with an implantable near-infrared spectroscopy sensor for glucose, ketones, lactate and ethanol · Peer-reviewed study · 2024-05-03 — GLOW/YANG predecessor, n=7 total and n=4 with T1D, implanted 28 days. Company-funded with company authors. Six of seven sensors remained operational; no infection/wound-healing complications; exploratory within-study glucose MARD 7.1% in the T1D participants.
De Ridder F, Braspenning R, Ordonez JS, et al. Early feasibility study with an implantable near-infrared spectroscopy sensor for glucose, ketones, lactate and ethanol. PLOS ONE (3 May 2024). n=7 total, n=4 T1D; 28-day implant; company-funded.
- [2]Indigo CMM sensor product and regulatory-status page · Manufacturer — Describes an implantable spectrometer for simultaneous metabolites and a one-year replacement target. Explicitly says not FDA-cleared, not CE-marked and not for sale. Retrieved 2026-08-08.
Indigo Diabetes. CMM Sensor / Our Product — implantable multi-metabolite spectrometer, intended phone link and annual replacement target; explicitly not FDA-cleared, not CE-marked and not for sale. Retrieved 8 Aug 2026.
- [3]Indigo reports completion of the six-month SHINE feasibility study · Manufacturer · 2025-03-20 — Company reports no device-related serious adverse events, long-term spectral collection and positive usability; no participant count or full accuracy dataset is published on the page.
Indigo Diabetes. SHINE Study Completed (20 Mar 2025) — company-reported six-month feasibility, no device-related serious adverse events and long-term spectral collection; no full accuracy dataset published on the page.
- [4]NCT07745998: BRIGHT study of the Indigo HALO System · Trial registry · 2026-08-04 — Not yet recruiting; estimated n=12 adults with T1D diagnosed for at least 12 months and using CSII. Primary performance endpoints compare glucose, ketone and lactate accuracy and stability with venous reference measurements over three months; estimated start December 2026.
ClinicalTrials.gov. The BRIGHT Study (Device Name: HALO System) (NCT07745998) — not yet recruiting; estimated n=12 adults with T1D diagnosed for at least 12 months and using CSII; primary performance endpoints cover glucose, ketone and lactate accuracy and stability versus venous reference measurements over three months; estimated Dec 2026-Jun 2027; posted 4 Aug 2026.